🎉 M&A multiples are live!
Check it out!

Celldex Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Celldex Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Celldex Therapeutics Overview

About Celldex Therapeutics

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.


Founded

1983

HQ

United States of America
Employees

186

Website

celldex.com

Financials

LTM Revenue $6.1M

LTM EBITDA -$200M

EV

$459M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Celldex Therapeutics Financials

Celldex Therapeutics has a last 12-month revenue of $6.1M and a last 12-month EBITDA of -$200M.

In the most recent fiscal year, Celldex Therapeutics achieved revenue of $7.0M and an EBITDA of -$192M.

Celldex Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Celldex Therapeutics valuation multiples based on analyst estimates

Celldex Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $6.9M $7.0M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$139M -$192M XXX XXX XXX
EBITDA Margin -2020% -2734% XXX XXX XXX
Net Profit -$112M -$141M XXX XXX XXX
Net Margin -1632% -2015% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Celldex Therapeutics Stock Performance

As of April 15, 2025, Celldex Therapeutics's stock price is $18.

Celldex Therapeutics has current market cap of $1.2B, and EV of $459M.

See Celldex Therapeutics trading valuation data

Celldex Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$459M $1.2B XXX XXX XXX XXX $-2.69

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Celldex Therapeutics Valuation Multiples

As of April 15, 2025, Celldex Therapeutics has market cap of $1.2B and EV of $459M.

Celldex Therapeutics's trades at 75.9x LTM EV/Revenue multiple, and -2.3x LTM EBITDA.

Analysts estimate Celldex Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Celldex Therapeutics and 10K+ public comps

Celldex Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $459M XXX XXX XXX
EV/Revenue 65.5x XXX XXX XXX
EV/EBITDA -2.4x XXX XXX XXX
P/E -7.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -2.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Celldex Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Celldex Therapeutics Valuation Multiples

Celldex Therapeutics's NTM/LTM revenue growth is -43%

Celldex Therapeutics's revenue per employee for the last fiscal year averaged $38K, while opex per employee averaged $1.1M for the same period.

Over next 12 months, Celldex Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Celldex Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Celldex Therapeutics and other 10K+ public comps

Celldex Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 2% XXX XXX XXX XXX
EBITDA Margin -2734% XXX XXX XXX XXX
EBITDA Growth 38% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -2776% XXX XXX XXX XXX
Revenue per Employee $38K XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 549% XXX XXX XXX XXX
R&D Expenses to Revenue 2330% XXX XXX XXX XXX
Opex to Revenue 2879% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Celldex Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Celldex Therapeutics M&A and Investment Activity

Celldex Therapeutics acquired  XXX companies to date.

Last acquisition by Celldex Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Celldex Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Celldex Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Celldex Therapeutics

When was Celldex Therapeutics founded? Celldex Therapeutics was founded in 1983.
Where is Celldex Therapeutics headquartered? Celldex Therapeutics is headquartered in United States of America.
How many employees does Celldex Therapeutics have? As of today, Celldex Therapeutics has 186 employees.
Who is the CEO of Celldex Therapeutics? Celldex Therapeutics's CEO is Mr. Anthony S. Marucci.
Is Celldex Therapeutics publicy listed? Yes, Celldex Therapeutics is a public company listed on NAS.
What is the stock symbol of Celldex Therapeutics? Celldex Therapeutics trades under CLDX ticker.
When did Celldex Therapeutics go public? Celldex Therapeutics went public in 1990.
Who are competitors of Celldex Therapeutics? Similar companies to Celldex Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Celldex Therapeutics? Celldex Therapeutics's current market cap is $1.2B
What is the current revenue of Celldex Therapeutics? Celldex Therapeutics's last 12-month revenue is $6.1M.
What is the current EBITDA of Celldex Therapeutics? Celldex Therapeutics's last 12-month EBITDA is -$200M.
What is the current EV/Revenue multiple of Celldex Therapeutics? Current revenue multiple of Celldex Therapeutics is 75.9x.
What is the current EV/EBITDA multiple of Celldex Therapeutics? Current EBITDA multiple of Celldex Therapeutics is -2.3x.
What is the current revenue growth of Celldex Therapeutics? Celldex Therapeutics revenue growth between 2023 and 2024 was 2%.
Is Celldex Therapeutics profitable? Yes, Celldex Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.